Drug Trial Radar · NCT04457856
A Study of TJ003234 in Rheumatoid Arthritis Patients
Last checked: Nov 19, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
63
Planned (sponsor's estimate)
Start
Aug 6, 2020
Primary completion
Mar 2023
Study completion Mar 2023
Sponsor
- Lead sponsor
- I-Mab Biopharma US LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Purpose and Design: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients.
Conditions
- Rheumatoid Arthritis
Interventions
TJ003234 injectionBiological
Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subject with adverse events(AEs)Time frame: First dose up to last follow-up visit (i.e. 90 days after dosing for single dose part, 140 days after first dose for multiple dose part)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of bengbu medical college
Bengbu, Anhui, China · Recruiting
Peking university people's Hospital
Beijing, Beijing Municipality, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Zhongda Hospital southeast university
Nanjing, Jiangsu, China · Recruiting
FuDan University shanghai huashan Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.